/Abbott%20Laboratories%20HQ%20photo-%20by%20Sundry%20Photography%20via%20iStock.jpg)
With a market cap of $233.8 billion, Abbott Laboratories (ABT) is a global healthcare company that discovers, develops, manufactures, and sells a diverse range of healthcare products across diagnostics, medical devices, nutritionals, and branded generics in emerging markets. Abbott has grown through strategic acquisitions, such as St. Jude Medical and Alere Inc., while streamlining its portfolio through divestitures, including its developed markets generics and vision care businesses.
The North Chicago, Illinois-based company is slated to announce its fiscal Q2 2025 earnings results before the market opens on Thursday, July 17. Ahead of the event, analysts are expecting ABT to report an adjusted EPS of $1.25, up 9.7% from $1.14 in the year-ago quarter. The company has met or surpassed Wall Street's bottom-line estimates in the past four quarterly reports. In Q1 2025, Abbott exceeded the consensus adjusted EPS estimate by 1.9%.
